Decreasing Edema With a Novel OCS Solution Trial

This is a prospective, multicenter randomized trial of lung transplant recipients transplanted with either a DBD or DCD donor lungs. The DENOVO Trial will enroll a total of 300 patients in the OCS arm and 150 patients in the SCS arm. The primary endpoint will be patient \& graft survival and freedom of Primary Graft Dysfunction (PGD) grade 3 within the initial 72 hours post-transplantation.

NCT Number	NCT07340710
Lead Sponsor	TransMedics
Conditions	Lung Transplant
Enrollment	450 participants
Start Date	2026-03
Primary Completion	2027-12 (estimated)
Study Completion	2028-02 (estimated)
Updated on ClinicalTrials.gov	2026-01-14